

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Ibrance

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

		Prescriber Name:			
Patient Name:		Supervising Physician			
		1			
Member/Subscriber Num	ber:	Fax:	Phone:		
Date of Birth:		Office Contact:			
Group Number:		NPI:	State Lic ID:		
Address:		Address:			
City, State ZIP:		City, State ZIP:			
Primary Phone:		Specialty/facility name (i	f applicable):		
Drug Name and Strength	:				
Directions / SIG:					
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.					
Q1. Please provide ICD code(s) for diagnosis.					
Q2. For which diagno	osis is Ibrance (palbociclib) being	prescribed?			
☐ Advanced or metastatic breast cancer					
☐ Other (please specify)					
Q3 Is prescribing ph	vsician a Hematology or Oncolog	nv specialist?			
Q3. Is prescribing physician a Hematology or Oncology specialist? ☐ Yes ☐ No					
Q4. Is the patient hor	mone receptor (HR) POSITIVE?				
Yes	□No				
O5 Is the nationt hur	man epidermal growth factor rece	entor 2 (HER2) NEGATIVE2			
Yes	□ No	pior 2 (HENZ) NEOATIVE:			
Q6. Will Ibrance (palbociclib) be used in combination with letrozole?					
Yes	☐ No				
Q7. Is the patient pos	stmenopausal?				



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Ibrance

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

		Prescriber Nan	ne:
Patient Name:		Supervising Pr	
☐ Yes	□No		
Q8. Will Ibrance (pa	albociclib) be used in combina	tion with fulvestrant?	
☐ Yes	☐ No		
Q9. Has patient had	d disease progression followin	g endocrine therapy?	
☐ Yes	□ No		
	d "no" to any of the questions a er recommendation per NCCI		ocumentation that use is consistent with a es.
Q11. Additional Cor	mments		
	Prescriber Signature		Date
	By checking this box and sign the life or health of the enrolled	•	applying the standard review timeframe may to regain maximum function
			uesting providers may speak to the SWHP medical the decision on a request before coverage has beer

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

decided.



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Ibrance

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:
Patient Name:	Supervising Physician: